Ascendis Pharma AS (FRA:A71) E10: €0.00 (As of Mar. 2026)


FRA:A71 Ascendis Pharma AS FRA:A71
37 GF Score
Price €206.00
! 5 Warning Signs
View Full Analysis

What is Ascendis Pharma AS E10?

Ascendis Pharma AS FRA:A71 +0.98% 37 E10 is €0.00 as of Mar. 2026. GuruFocus rates FRA:A71 with a GF Score™ of 37/100. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Ascendis Pharma AS's adjusted earnings per share data for the three months ended in Mar. 2026 was €0.000. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €0.00 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-08), Ascendis Pharma AS's current stock price is €206.00. Ascendis Pharma AS's E10 for the quarter that ended in Mar. 2026 was €0.00. Ascendis Pharma AS's Shiller PE Ratio of today is .


Ascendis Pharma AS  (FRA:A71) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Ascendis Pharma AS E10 Related Terms


Ascendis Pharma AS E10 Historical Data

* Premium members only.

The historical data trend for Ascendis Pharma AS's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Pharma AS E10 Chart

Ascendis Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -5.62 -6.63 -6.07

Ascendis Pharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.49 -6.10 -6.20 -6.07 0.00

FRA:A71 vs JAZZ, BBIO, EXEL: E10 Comparison

For the Biotechnology subindustry, Ascendis Pharma AS's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascendis Pharma AS Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma AS's Shiller PE Ratio falls into.


FRA:A71
37GF Score
Ascendis Pharma AS FRA:A71
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascendis Pharma AS E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ascendis Pharma AS's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/121.6800*121.6800
=0.000

Current CPI (Mar. 2026) = 121.6800.

Ascendis Pharma AS Quarterly Data

per share eps CPI Adj_EPS
201606 -0.530 100.600 -0.641
201609 -0.720 100.200 -0.874
201612 -0.510 100.300 -0.619
201703 -0.780 101.200 -0.938
201706 -0.940 101.200 -1.130
201709 -1.040 101.800 -1.243
201712 -0.920 101.300 -1.105
201803 -1.070 101.700 -1.280
201806 -0.550 102.300 -0.654
201809 -0.810 102.400 -0.963
201812 -0.760 102.100 -0.906
201903 -1.240 102.900 -1.466
201906 -1.250 102.900 -1.478
201909 -0.530 102.900 -0.627
201912 -1.700 102.900 -2.010
202003 -1.320 103.300 -1.555
202006 -1.970 103.200 -2.323
202009 -2.310 103.500 -2.716
202012 -2.640 103.400 -3.107
202103 -1.170 104.300 -1.365
202106 -2.500 105.000 -2.897
202109 -1.470 105.800 -1.691
202112 -1.870 106.600 -2.135
202203 -2.210 109.900 -2.447
202206 -1.460 113.600 -1.564
202209 -3.030 116.400 -3.167
202212 -3.700 115.900 -3.885
202303 -1.980 117.300 -2.054
202306 -2.160 116.400 -2.258
202309 -2.880 117.400 -2.985
202312 -1.540 116.700 -1.606
202403 -2.300 118.400 -2.364
202406 -2.210 118.500 -2.269
202409 -1.720 118.900 -1.760
202412 -0.640 118.900 -0.655
202503 -1.580 120.200 -1.599
202506 -0.820 120.700 -0.827
202509 -1.000 121.600 -1.001
202512 -0.550 121.200 -0.552
202603 0.000 121.680 0.000

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €0.00 mean?
Ascendis Pharma AS (FRA:A71) has a E10 of €0.00 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Ascendis Pharma AS and its competitors.
Is Ascendis Pharma AS's E10 too high?
Ascendis Pharma AS's current E10 is €0.00. Overall, Ascendis Pharma AS has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's E10 compare to JAZZ and BBIO?
Ascendis Pharma AS's E10 of €0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Ascendis Pharma AS and its competitors. Ascendis Pharma AS's current E10 is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (FRA:A71) has a current E10 of €0.00. The current E10 is €0.00. Ascendis Pharma AS's overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Ascendis Pharma AS (FRA:A71), the current E10 is €0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascendis Pharma AS Business Description

Other Exchanges ASND:USA
Address Tuborg Boulevard 12, Hellerup, DNK, 2900
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
37GF Score

Get the complete analysis for FRA:A71

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€206.00
Price